Sterling Capital Management’s Definium Therapeutics DFTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$157K Buy
4,128
+3,671
+803% +$155K ﹤0.01% 1236
2026
Q2
$21.5K Sell
457
-1,986
-81% -$49.1K ﹤0.01% 1854
2026
Q1
$46.2K Sell
2,443
-1,472
-38% -$25K ﹤0.01% 1673
2025
Q4
$52.4K Buy
3,915
+284
+8% +$3.52K ﹤0.01% 1785
2025
Q3
$42.8K Buy
3,631
+2,175
+149% +$20.3K ﹤0.01% 1805
2025
Q2
$9.45K Buy
1,456
+1,369
+1,574% +$9K ﹤0.01% 2167
2025
Q1
$509 Buy
87
+13
+18% +$93 ﹤0.01% 2953
2024
Q4
$515 Hold
74
– – ﹤0.01% 3030
2024
Q3
$421 Buy
+74
New +$515 ﹤0.01% 2936

Other funds holding DFTX

Sterling Capital Management's DFTX Position: Q3 2026 in Review

Sterling Capital Management increased its Definium Therapeutics (DFTX) stake by 803% in Q3 2026, buying an estimated $155K and bringing the position to 4,128 shares worth $157K. The position accounts for ﹤0.01% of the portfolio, ranked #1236.

Sterling Capital Management first reported a position in DFTX in Q3 2024 and has held it in 9 quarters since. 302 funds tracked by Wall St. Rank hold DFTX as of Q3 2026.

  • Sterling Capital Management held 4,128 shares of Definium Therapeutics worth $157K as of Q3 2026.
  • Sterling Capital Management bought 3,671 Definium Therapeutics shares in Q3 2026, an estimated $155K.
  • Definium Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q3 2026, its #1236 holding.
  • Sterling Capital Management first reported a position in Definium Therapeutics in Q3 2024 and has held it in 9 quarters since.
  • 302 funds tracked by Wall St. Rank held Definium Therapeutics as of Q3 2026.

Based on Sterling Capital Management's 13F filing for Q3 2026, filed 22 Oct 2026.